Characteristics of study patient samples
| ID no. . | Age, y/sex . | Stage (Binet) . | Prior treatment . | Cytogenetic aberrations . | IgVH2 . | ZAP-70* . | CD38* . | % viable relative to control after treatment with 5 μM dasatinib . |
|---|---|---|---|---|---|---|---|---|
| 1 | 73/F | A | yes | none | M | n.d. | n.d. | n.d. |
| 2 | 65/M | A | no | n.d. | M | − | − | 65.5 |
| 3 | 58/M | A | no | trisomy 12 | M | − | + | 72.4 |
| 4 | 83/M | C | yes | n.d. | M | − | n.d. | n.d. |
| 6 | 69/M | C | yes | n.d. | um | + | + | 36.1 |
| 7 | 58/F | B | yes | n.d. | n.d. | n.d. | n.d. | 77.4 |
| 8 | 67/M | B | no | Δ13q14 | M | − | − | 80.5 |
| 9 | 63/F | A | no | n.d. | n.d. | − | − | 78.3 |
| 10 | 60/F | C | no | n.d. | n.d. | − | − | 82.4 |
| 11 | 49/M | A | no | none | M | + | − | 73.3 |
| 12 | 59/M | C | no | n.d. | M | − | − | 70.4 |
| 16 | 54/M | B | no | Δ13q14 | um | + | − | 17.4 |
| 17 | 62/M | B | no | Δ11q (ATM) | um | + | + | 39.1 |
| 18 | 66/M | C | no | n.d. | n.d. | + | − | n.d. |
| 19 | 75/F | n.d. | no | Δ13q14 | um | − | + | 41.8 |
| 22 | 64/M | C | no | n.d. | n.d. | − | − | 67.5 |
| 23 | 64/M | B | n.d. | Δ11q (ATM) | M | − | − | 53.2 |
| 25 | 59/M | n.d. | no | n.d. | n.d. | + | − | 50.7 |
| 26 | 48/M | n.d. | no | Δ6q21, Δ17p (p53) | um | + | + | 38.6 |
| 27 | 57/M | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 70.3 |
| 28 | 49/M | A | no | Δ13q14 | M | − | − | 79.3 |
| 29 | 58/M | A | no | n.d. | n.d. | + | − | 83.1 |
| 30 | 65/M | C | yes | n.d. | n.d. | n.d. | n.d. | 54.2 |
| 31 | 76/M | B | yes | n.d. | n.d. | + | + | 37.4 |
| 32 | 72/M | B | yes | n.d. | M | − | − | 88.0 |
| 33 | 66/M | B | yes | n.d. | n.d. | − | − | 74.1 |
| 34 | 42/M | A | no | Δ11q (ATM) | um | n.d. | n.d. | 79.7 |
| 35 | 88/F | B | yes | n.d. | M | − | n.d. | 71.2 |
| ID no. . | Age, y/sex . | Stage (Binet) . | Prior treatment . | Cytogenetic aberrations . | IgVH2 . | ZAP-70* . | CD38* . | % viable relative to control after treatment with 5 μM dasatinib . |
|---|---|---|---|---|---|---|---|---|
| 1 | 73/F | A | yes | none | M | n.d. | n.d. | n.d. |
| 2 | 65/M | A | no | n.d. | M | − | − | 65.5 |
| 3 | 58/M | A | no | trisomy 12 | M | − | + | 72.4 |
| 4 | 83/M | C | yes | n.d. | M | − | n.d. | n.d. |
| 6 | 69/M | C | yes | n.d. | um | + | + | 36.1 |
| 7 | 58/F | B | yes | n.d. | n.d. | n.d. | n.d. | 77.4 |
| 8 | 67/M | B | no | Δ13q14 | M | − | − | 80.5 |
| 9 | 63/F | A | no | n.d. | n.d. | − | − | 78.3 |
| 10 | 60/F | C | no | n.d. | n.d. | − | − | 82.4 |
| 11 | 49/M | A | no | none | M | + | − | 73.3 |
| 12 | 59/M | C | no | n.d. | M | − | − | 70.4 |
| 16 | 54/M | B | no | Δ13q14 | um | + | − | 17.4 |
| 17 | 62/M | B | no | Δ11q (ATM) | um | + | + | 39.1 |
| 18 | 66/M | C | no | n.d. | n.d. | + | − | n.d. |
| 19 | 75/F | n.d. | no | Δ13q14 | um | − | + | 41.8 |
| 22 | 64/M | C | no | n.d. | n.d. | − | − | 67.5 |
| 23 | 64/M | B | n.d. | Δ11q (ATM) | M | − | − | 53.2 |
| 25 | 59/M | n.d. | no | n.d. | n.d. | + | − | 50.7 |
| 26 | 48/M | n.d. | no | Δ6q21, Δ17p (p53) | um | + | + | 38.6 |
| 27 | 57/M | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 70.3 |
| 28 | 49/M | A | no | Δ13q14 | M | − | − | 79.3 |
| 29 | 58/M | A | no | n.d. | n.d. | + | − | 83.1 |
| 30 | 65/M | C | yes | n.d. | n.d. | n.d. | n.d. | 54.2 |
| 31 | 76/M | B | yes | n.d. | n.d. | + | + | 37.4 |
| 32 | 72/M | B | yes | n.d. | M | − | − | 88.0 |
| 33 | 66/M | B | yes | n.d. | n.d. | − | − | 74.1 |
| 34 | 42/M | A | no | Δ11q (ATM) | um | n.d. | n.d. | 79.7 |
| 35 | 88/F | B | yes | n.d. | M | − | n.d. | 71.2 |
n.d. indicates not determined; um, unmutated (<2% sequence divergence with the closest germline gene); M, mutated (>2% sequence divergence with the closest germline gene).
+ indicates that more than 20% of cells and − indicates that less than 20% percentage of cells showed higher fluorescence after specific antibody staining than after isotype antibody staining.